Back

Long-Term Organ Culture Reveals Differential Stem Cell-Driven Remodelling in Myometrium and MED12-Mutant Uterine Leiomyoma

Vazquez, P.; Salas, A.; Beltran-Flores, S.; Montes de Oca, F.; Delgado, A.; Almeida, T.

2025-08-22 molecular biology
10.1101/2025.08.19.670360 bioRxiv
Show abstract

Uterine leiomyomas or fibroids are highly prevalent benign tumors of the female reproductive tract, often causing significant symptoms and requiring surgical intervention, leading to substantial healthcare costs worldwide. Their molecular pathogenesis remains incompletely understood, but evidence suggests that somatic stem cells play a pivotal role in myometrial growth, whereas a genetic alteration, particularly mutations in MED12, may transform a myometrial stem cell into a tumor-initiating cell, promoting fibroid growth. In organ cultures of fibroids and myometrium, most differentiated cells degenerated by day 7, whereas stem cells remained quiescent and viable within their native niches. Notably, between days 15 and 29, hypoxia-induced activation triggered stem cell proliferation and differentiation within the ex vivo slices. Transcriptomic profiling revealed statistically significant upregulation of stemness-associated genes, including HMGA, ITG, KLF, HOX, and SOX family members, in long-term cultured slices compared with baseline tissue, and between normal and tumor cultures. Reactome pathway enrichment analysis further identified distinct metabolic, extracellular matrix remodeling, immune surveillance, angiogenic, and cell death- related programs distinguishing myometrial from leiomyoma cultures. Furthermore, previously reported gene and pathway differences between healthy and fibroid tissues were robustly confirmed, validating the culture model. In conclusion, our findings establish long-term organ culture as a powerful, physiologically relevant platform for investigating stem cell dynamics in myometrium and uterine leiomyoma. They also provide proof of concept for extending this approach to other tissue types, enabling the discovery of mechanisms underlying stem cell activation, differentiation, and death, with broad translational potential in regenerative medicine and cancer biology.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3612 papers in training set
Top 3%
11.5%
2
Stem Cell Research & Therapy
30 papers in training set
Top 0.1%
7.6%
3
Molecular Medicine
11 papers in training set
Top 0.1%
5.7%
4
Communications Biology
993 papers in training set
Top 1%
5.7%
5
Nature Communications
5641 papers in training set
Top 31%
4.2%
6
Cells
249 papers in training set
Top 0.7%
3.7%
7
Stem Cell Reports
130 papers in training set
Top 0.7%
3.4%
8
Stem Cells
31 papers in training set
Top 0.2%
2.9%
9
PLOS ONE
5266 papers in training set
Top 42%
2.5%
10
Communications Medicine
113 papers in training set
Top 2%
2.0%
11
iScience
1154 papers in training set
Top 16%
1.8%
50% of probability mass above
12
Journal of Cellular and Molecular Medicine
20 papers in training set
Top 0.2%
1.8%
13
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 2%
1.8%
14
International Journal of Molecular Sciences
494 papers in training set
Top 8%
1.6%
15
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.4%
1.2%
16
Experimental Cell Research
28 papers in training set
Top 0.5%
1.1%
17
Cell Death & Disease
126 papers in training set
Top 3%
1.1%
18
NAR Molecular Medicine
22 papers in training set
Top 0.2%
1.0%
19
Cell Death Discovery
58 papers in training set
Top 1%
1.0%
20
eBioMedicine
183 papers in training set
Top 6%
0.9%
21
Cell Communication and Signaling
51 papers in training set
Top 1%
0.9%
22
Laboratory Investigation
13 papers in training set
Top 0.2%
0.9%
23
The FASEB Journal
194 papers in training set
Top 5%
0.9%
24
Cancers
213 papers in training set
Top 4%
0.9%
25
Frontiers in Medicine
120 papers in training set
Top 5%
0.6%
26
Oncogenesis
12 papers in training set
Top 0.4%
0.6%
27
Life Science Alliance
285 papers in training set
Top 8%
0.6%
28
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 3%
0.6%
29
Frontiers in Oncology
103 papers in training set
Top 3%
0.6%
30
Experimental & Molecular Medicine
14 papers in training set
Top 0.1%
0.6%